Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?
Geroscience
; 44(3): 1263-1268, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1838400
ABSTRACT
Since the appearance of coronavirus disease 2019 (COVID-19), numerous studies have been conducted to find effective therapeutics. Favipiravir (FVP) is one of the repurposed drugs which has been authorized in a few countries on an emergency basis to treat COVID-19. Elderly individuals especially 65 years or older are more prone to develop severe illness. We aim to provide a short summary of the current knowledge of the antiviral efficacy of favipiravir with respect to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected elderly patients. We found that it is rather controversial whether favipiravir is effective against SARS-CoV-2 infection. Data regarding patients 65 years or older is not sufficient to support or reject the usage of favipiravir for COVD-19 treatment. Further studies would be advisable to elicit the efficiency of favipiravir in elderly COVID-19 patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Type of study:
Prognostic study
Limits:
Aged
/
Humans
Language:
English
Journal:
Geroscience
Year:
2022
Document Type:
Article
Affiliation country:
S11357-022-00582-8
Similar
MEDLINE
...
LILACS
LIS